ENTITY
Ascentage Pharma

Ascentage Pharma (6855 HK)

69
Analysis
Health Care • China
Ascentage Pharma is a clinical-stage biotechnology company focused on discovering, developing, and commercializing novel small-molecule therapies for cancers, hepatitis B virus, and certain age-related diseases. The company specializes in therapies that inhibit protein-protein interactions to restore programmed cell death, with lead assets including olverembatinib and lisaftoclax for hematological malignancies. Ascentage Pharma was founded in 2009 and is headquartered in Suzhou, China.
more
bullish•Alibaba
•22 Jun 2019 12:52

ECM Weekly (22 Jun 2019) -  Alibaba, Budweiser Brewing Co, Ascentage, CIMC Vehicle, Impro Precision

Aequitas Research puts out a weekly update on the deals that have been covered by Smartkarma Insight Providers recently, along with updates for...

Share
•19 Jun 2019 13:02

Ascentage Pharma (亚盛医药) IPO: Updates and Thoughts on HQP1351 (3rd Gen Bcr-Abl TKI)

Ascentage Pharma is pre-marketing the USD 200 - 300 million IPO to list in Hong Kong. In our previous insight, we highlight the company's key...

Logo
1k Views
Share
•07 Dec 2018 15:32

Ascentage Pharma (亚盛医药) IPO: Too Early for an IPO

Ascentage Pharma, a China-based biotech company, filed an application to list on the Hong Kong Stock Exchange. In this insight, we will cover the...

Logo
1.5k Views
Share
x